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ABSTRACT 
The primary aim of the present study was to investigate Facial Emotion Recognition (FER) in 
patients with Somatoform Disorders (SFD). Also of interest was the extent to which 
concurrent alexithymia contributed to any changes in emotion recognition accuracy. Twenty 
patients with SFD and twenty healthy, age, sex and education matched, controls were 
assessed with the FEEL Test of facial emotion recognition and the 26-item Toronto 
Alexithymia Scale (TAS-26). Patients with SFD exhibited elevated alexithymia symptoms 
relative to healthy controls. Patients with SFD also recognized significantly fewer emotional 
expressions than did the healthy controls. However, the group difference in emotion 
recognition accuracy became non-significant once the influence of alexithymia was controlled 
for statistically. This suggests that the deficit in facial emotion recognition observed in the 
patients with SFD was most likely a consequence of concurrent alexithymia. It should be 
noted that neither depression nor anxiety were significantly related to emotion recognition 
accuracy, suggesting that these variables did not contribute the emotion recognition deficit. 
Impaired facial emotion recognition observed in the patients with SFD could plausibly have a 
negative influence on these individuals’ social functioning.  
     
(f) Key words: Alexithymia - Emotion Recognition - Somatoform Disorders  
 
Abbreviations: FEEL=Facially Expressed Emotion Labelling Test; FER=Facial Emotion 
Recognition; SFD=Somatoform Disorders; TAS-26= Toronto Alexithymia Scale-26 Items 
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INTRODUCTION 
Somatoform disorders (SFD) refer to a group of psychiatric conditions that are 
characterized by, often multiple and variable, somatic symptoms (e.g. limb pain, stomach 
disturbance) that are commonly seen in general medical practice and primary care but that 
defy medical explanation [Ustun and Sartorius, 1995]. It has been reported recently that 
patients with a subtype of SFD, namely body dysmorphic disorder (BDD), exhibit impaired 
ability to correctly identify facially expressed emotion. Buhlmann et al. [2004] reported that a 
group of 20 patients with BDD exhibited a general impairment, relative to matched healthy 
controls, in their recognition of the primary emotions from facial stimuli. This finding was 
replicated by the same research group in a subsequent study [Buhlmann et al., 2006]. To 
date, no studies have addressed if other forms of SFD are associated with a similar deficit in 
facial emotion recognition. This is an important avenue of research as such a deficit could 
contribute to the interpersonal problems that have been reported in patients with SFD [Waller 
et al., 2004].   
A concept that might contribute to our understanding of facial emotion recognition in 
patients with SFD is alexithymia. This concept was developed by Sifneos [1973] and is 
characterized by an inability to describe and identify one’s own feelings, the absence of 
fantasies, and the utilization of an externally oriented analytical cognitive style. Notably, 
alexithymia has also been implicated in problems in the recognition of facially expressed 
emotion. For example, a number of studies [e.g. Jessimer et al., 1997; Lane et al., 2000; 
Parker et al., 1993] have reported that individuals meeting (TAS-20) criteria for alexithymia 
exhibited significantly impaired emotion recognition from facial stimuli relative to non-
alexithymic participants.  With these findings in mind, it has been suggested [Lane et al., 
2000] that the commonly reported problems in putting emotion into words in alexithymia 
might represent a more general impairment in emotional information processing. 
It is notable that elevated levels of alexithymia have been reported in a number of 
clinical disorders; including depression [Honkalampi et al., 2000], eating disorders 
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[Bydlowski, 2005], and obsessive-compulsive disorder [De Berardis et al., 2005] that have 
also been shown to exhibit deficits in emotion recognition from faces [Aigner et al., 2006; 
Dannlowski et al. 2006; Gaebel et al., 1992; Gaebel et al., 2004; Leppänen et al., 2004; 
Weniger et al., 2004]. It is plausible that the presence of alexithymia in these clinical groups 
might have contributed to their problems in recognizing emotion from faces. Importantly for 
the present study, a high prevalence of alexithymia has also been shown in patients with 
SFD [Bach and Bach, 1995; Bankier et al., 2001]. 
The main aim of the present study was to investigate if patients with SFD exhibit 
impaired recognition of facially expressed emotion. Also of interest was the extent to which 
concurrent alexithymia contributed to any observed deficits in emotion recognition. With this 
in mind, a carefully selected sample of patients with SFD and a group of healthy controls 
were assessed on a widely used test of facial emotion recognition [FEEL Test; Kessler et al., 
2002]. The presence and severity of alexithymia was established using a robust measure of 
alexithymia [TAS-26; Kupfer et al., 2000; 2001]. It was expected that patients with SFD would 
correctly recognize fewer emotional facial expressions than would the controls. However, it 
was also expected that this effect would be mediated by the presence of concurrent 
alexithymia. 
METHODS 
PARTICIPANTS 
Twenty psychiatric outpatients (16 females, 4 males) meeting ICD-10 diagnostic 
criteria for SFD and twenty healthy, age and sex matched, controls (15 females, 5 males) 
took part in the present study. These sample sizes were considered large enough to enable 
changes in emotion recognition accuracy in patients with SFD to be detected; as they are 
directly comparable with the sample sizes used in the only other studies that have reported 
impaired facial emotion recognition in patients with sub-types of SFD [Buhlmann et al., 2004; 
2006].  Nine of the 20 patients with SFD were diagnosed with persistent somatoform pain 
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disorder (F45.4), seven with somatization disorder (F45.0) and four with somatoform 
autonomic dysfunction (F45.3). The patients with SFD were recruited from an outpatient 
clinic of the Department of Medicine (Munich University) and the psychotherapy ward of 
“Psychosomatic Hospital” in Simbach, where they had been referred for diagnostic interview 
and counselling. The diagnosis of SFD was established during a standardized clinical 
interview based on the diagnostic criteria outlined in the ICD-10 [Hiller et al., 1996] and on 
the participant’s score on the Screening for Somatoform Symptoms (SOMS) questionnaire 
[Rief et al., 1997]. Diagnosis was based on medical and psychiatric assessment performed 
by a trained psychiatrist (P.G.F.). Inclusion criteria for the patient group were the presence of 
a SFD, diagnosed according to ICD-10 criteria. Physical conditions (e.g. angina) that may 
have explained the patient’s symptoms had been excluded prior to referral following 
extensive inpatient or outpatient investigation at the Department of Medicine or in general 
practice. It should be noted that 80% (n = 16) of the SFD patients also exhibited symptoms of 
co-morbid psychiatric conditions. The most common conditions were (F34.1) dysthymia (n = 
7) and (F43.2) brief depressive reaction (n = 4), further co-morbid diagnoses were three 
cases of anxiety disorder (F41.1), one case of hypochondriasis (F45.2) and one case 
exhibited the symptom profile of mixed anxiety and depressive disorder (F41.2). Exclusion 
criteria for the patient group were presence of medical disorders (e.g. autoimmune-, 
neoplasms, cardiac-, pulmonary-, or endocrine diseases), severe mental illnesses, such as 
schizophrenia, schizoaffective disorder, bipolar disorder, substance abuse disorders, major 
depression (unipolar with depressive episodes), medication with benzodiazepines or other 
psychotropic drugs during the past four weeks. The latter criteria were to ensure that the 
patients were entirely drug free at the time of testing in order to eliminate any possible 
pharmacological influences upon facial emotion recognition. 
The participants in the control group were recruited from the local community and 
from the student population in the medical and nursing schools at the University of Ulm. Prior 
to taking part in the present study the participants making up the control group reported that 
they were not currently suffering from any serious medical or psychiatric conditions and that 
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were not currently taking any psychotropic medication. It should be noted that no thorough 
clinical examination was conducted on these individuals to confirm their self-reported medical 
and psychological status. Controls were matched with the SFD patients in terms of age and 
sex, and educational background. Additionally in the control group only the FEEL-test and 
the TAS-26 were measured, no more psychological measures were accomplished. 
 
The study protocol was approved by the Ethics Committee of the University of Ulm 
and Munich and full written informed consent was obtained from each participant before they 
took part in the study. 
 
MEASURES AND ASSESSMENTS  
The original version of TAS (Toronto Alexithymia Scale) was developed by Taylor et 
al. [1992] as a standardized self-assessment questionnaire to measure alexithymia. A 
German version of this measure (TAS-26) has subsequently been developed by Kupfer et al. 
[2000; 2001], which consists of 26 items that are rated on a 5-point Likert scale. The TAS-26 
was utilized in the present study to assess the presence and severity of alexithymia in the 
participants. A three-factor structure has been replicated in clinical and non-clinical groups: 
This measure includes 26 items that generate scores on three dimensions: “difficulty 
identifying feelings”; “difficulty describing feelings” and “externally orientated thinking”. The 
German version was validated with a representative population sample (n=2084) and shows 
adequate internal consistencies ranging between r=.67 and r=.84.  
The Screening for Somatoform Symptoms [SOMS; Rief et al., 1997] is a self-rated 
questionnaire that was used in the present study to establish the presence of 53 physical 
symptoms. The symptoms incorporated in the questionnaire include all 33 physical 
complaints outlined in the DSM-IV criteria for somatoform disorders and the somatic 
symptoms listed in the ICD-10. The "somatization index" is computed by summing the 
number of reported symptoms (scores range from 0 to 33 points). The number of self-
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reported somatization symptoms correlated (r = 0.75) with the number identified during the 
clinical interview, confirming the high validity of the SOMS.  
The 90-item version of the Symptom Checklist-90 Revised [SCL-90-R; Derogatis, 
1994] is a widely used self-report questionnaire that assesses the presence and severity 
(using 5-point Likert scales) of symptoms of a number of somatic and psychiatric conditions. 
The 21-item Hamilton Rating Scale for Depression; [HAMD; Hamilton, 1960] was utilized in 
the present study to provide an observer-rated measure of depression severity. This 
assessment was conducted by a fully trained psychiatrist (P.G.F).  
 
ASSESSMENT OF EMOTION RECOGNITION ACCURACY 
The Facially Expressed Emotion Labelling (FEEL) Test [Kessler et al., 2002] was 
utilized in the present study to assess participants’ ability to recognize the basic emotions 
from facial stimuli. The FEEL Test is a computer-based program that involves presenting 
participants with color photographs of faces expressing different emotions and asking them 
to identify the emotion expressed. The faces included in the FEEL Test were taken from the 
JACFEE series (Japanese and Caucasian Facial Expressions of Emotion) developed by 
Matsumoto et al. [1988] and feature the six basic emotions: anger, sadness, disgust, fear, 
happiness and surprise. In total, there are 42 pictures making up the FEEL Test (the six 
basic emotions are each represented by seven different faces). Although half of the 
emotional expressions were portrayed by Japanese individuals and half by Caucasian, 
unpublished data from our own research group, based on a sample of healthy participants 
(n=400), revealed no differences between posers in terms of FEEL score [Traue, Keller, 
Hoffmann, Kessler, in preparation]. The FEEL Test was considered to be the most suitable 
task to assess emotion recognition ability in the present study, as it has already been used 
with several hundred participants [Traue, Keller, Hoffmann, Kessler, in preparation ] and has 
been shown to have a Cronbach´s alpha coefficient of up to r= 0.77 [Kessler et al., 2002].  
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PROCEDURE 
The participants completed the interview and questionnaires, followed by the FEEL 
Test on the same day. After a practice phase to get accustomed with the testing procedure, 
the 42 pictures making up the main set of stimuli in the FEEL Test were presented to the 
participants, one at a time in a random order, according to the following protocol. First, a 
neutral face was shown on the computer screen for 1500 milliseconds (ms) and this was 
accompanied by a short beep to attract the attention of the participant. After a break of 
1000ms an expressive stimulus (same face, this time showing one of the six basic emotions) 
was presented for exactly 300ms. The use of both the neutral and the emotional facial 
expression was considered necessary because some of the stimuli (neutral face per se) 
might have provoked emotional interpretations due to their physiognomy. Furthermore, the 
presentation of a neutral face followed by an emotional expression imitates natural conditions 
where the emotion often evolves from the neutral face. Once the emotional face had 
disappeared from the screen there was an interval of 500ms after which time, six emotion 
words (one for each basic emotion) were displayed on the screen. The participant indicated, 
by clicking on the appropriate word label, which emotion they considered had been portrayed 
by the previously presented face (forced-choice response format). It is important to note that 
the emotional picture and the labels were not visible on the screen at the same time. The 
maximum time allowed for the participant to make their response was 10 seconds. Prior to 
the presentation of the next pair of faces (neutral and then emotional) there was a variable 
pause of between 4000 to 6000 milliseconds, during which time the screen was grey. Once 
the participants had viewed and rated all of the faces they were thanked for their participation 
and fully de-briefed concerning the aims and objectives of the present study.  
 
SCORING AND DATA ANALYSIS 
Prior to statistical analysis all data were examined to ensure they met parametric 
assumptions. Shapiro-Wilk tests were utilized to establish if the data was normally distributed 
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and Levene Tests were conducted to check for the homogeneity of variance.  All data met 
parametric test assumptions unless otherwise stated.   
The age of the participants in the two groups was analyzed using an independent t-
test. The ratio of male and females making up each sample and the number of participants 
from each group achieving the highest level of education were analyzed using chi-square 
tests. The participants’ alexithymia (TAS-26) scores were analyzed using independent t-tests 
with the alpha level adjusted (p=0.0125) for multiple comparisons using Bonferroni 
correction.  Prior to statistical analysis, the total number of each type of facial expression that 
was correctly recognized by each participant was calculated to provide a FEEL score for 
each emotion (ranging from 0 to 7) and these scores were summed to give the participants’ 
total FEEL score (ranging from 0 to 42). The participants’ FEEL scores were analyzed using 
a 2 x 6 mixed ANOVA with group (patients with SFD vs. controls) as the between subjects 
factor and the type of emotional expression (happiness vs. sadness vs. surprise vs. anger vs. 
fear vs. disgust) as the within subjects factor. As the Shapiro-Wilk tests revealed that the 
FEEL data was not normally distributed these data were subjected to an arcsine 
transformation prior to statistical analysis [according to the procedure outlined in Keppel and 
Wickens, 2004]. Although this transformation failed to fully correct the distribution of all of the 
data, analysis was still conducted using the planned ANOVA, as it has been reported 
consistently that the F-test is robust even if the normality assumption is violated [Keppel and 
Wickens, 2004]. It is important to note that the data did not violate the homogeneity of 
variance assumption. For ease of understanding, the untransformed data are presented in 
table 2. In order to control for the influence of alexithymia on emotion recognition accuracy 
the analysis was re-conducted with the participants’ TAS-26 scores entered as a covariate. 
The resultant adjusted mean FEEL scores are presented in table 3. Pearson correlation 
coefficients were calculated to analyze the significance of the relationships between 
participants’ SOMS and SCL-90-R (somatization subscale) scores and self-rated alexithymia 
(indexed by TAS-26 scores). Similarly, Pearson tests were used to assess the significance of 
the relationships between participants’ HAM-D, SOMS, SCL-90-R (GSI, Depression, Anxiety 
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and Somatization scales) scores and emotion recognition accuracy. All analysis was 
conducted using SPSS for Windows© 12.0.  
RESULTS 
PARTICIPANT CHARACTERISTICS AND PSYCHOPATHOLOGY  
Analysis of the participant characteristics revealed that the two groups did not differ 
significantly in terms of their age (SFD patients Mean=47.7 years, Standard Deviation=8.5; 
healthy controls (HC) M=46.4 years, SD=9.4); t(38)=0.5, p>0.05. Furthermore, the two 
groups did not differ significantly in terms of the ratio of males and females making up each 
group, χ2(1)=0.14, p>0.05. Likewise, the two groups did not differ in terms of their 
educational background, with eight patients with SFD and 6 healthy controls having 
completed higher level study; χ2(1)=0.4, p>0.05. Inspection of the SOMS scores of the SFD 
patients (M=18.7, SD=10.5) revealed moderate to severe levels of somatization. Examination 
of the HAMD scores (M=11.7, SD=4.3) revealed that the patients with SFD were also 
experiencing a mild degree of depression severity. Subjective general psychiatric symptoms 
as indicated by the Global Severity Index-score (SCL-90-R) were elevated (M=63.6, 
SD=12.9) in patients with SFD relative to the normative sample mean of 50 (SD=10).  
  
ASSESSMENT OF ALEXITHYMIA  
Analysis of the participants’ total alexithymia (TAS-26) scores (presented in table 1) 
revealed that patients with SFD rated themselves as significantly more alexithymic (M=52.7, 
SD=9.9) than did healthy controls (M=42.9, SD=10.5); t(38)=3.0, p<0.01. Furthermore, 
analysis of the participants’ scores on the three factors of the TAS-26 revealed that patients 
with SFD scored significantly higher on the factor 1 “Difficulty identifying feelings“(M=56.0, 
SD=10.1) than did the controls (M=44.6, SD=8.2); t(38)=3.9, p<0.001. However, the scores 
of the patients did not differ from those of the controls on either the factor 2 “Difficulty 
describing feelings“ (SFD M=49.7, SD=13.4; controls M=44.5, SD=11.5) or factor 3 
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“Externally oriented thinking“ subscales (SFD M=48.6, SD=9.3; controls M=45.6, SD=10.4); 
t(38)=1.3, p>0.05 and t(38)=1.0, p>0.05 respectively. As the significant difference between 
the groups in alexithymia could confound the interpretation of the participants’ emotion 
recognition performance the alexithymia scores were entered into the analysis of the emotion 
recognition accuracy as a covariate (see data analysis section above). Correlational 
analyses revealed no significant relationships between self-rated somatization (indexed by 
participants’ scores on the SOMS and the somatization subscale of the SCL-90-R) and the 
degree of alexithymia (indexed by TAS-26 scores), all tests p>0.05.  
 
ASSESSMENT OF EMOTION RECOGNITION ACCURACY 
Analysis of the participants’ emotion recognition accuracy (FEEL scores; presented in 
table 2) revealed a significant effect of participant group, such that patients with SFD 
correctly recognized fewer emotional expressions (Mean=31.7, Standard deviation=4.6) than 
did the healthy controls (M=34.5, SD=3.0); F(1, 38)= 5.3, p<0.05. The analysis also revealed 
a significant main effect of type of emotion on the participants’ FEEL scores; F(5,190)=23.9, 
p<0.001. However, no significant Group x Type of Emotion interaction was observed; F(5, 
190)=1.2, p>0.05. Further investigation of the main effect of type of emotion, using 
Bonferroni adjusted t-tests, revealed that the participants exhibited more accurate recognition 
of anger than fear, sadness or disgust; p<0.05, p<0.001 and p<0.01 respectively.  Similarly, 
happiness was recognized more accurately than fear, sadness or disgust; all tests p<0.001. 
Furthermore, happiness was recognized more accurately than was surprise; p<0.05. The 
accuracy of participants’ recognition of happiness and anger did not differ significantly; 
p>0.05. Likewise, participants did not differ in their recognition of sadness, disgust, fear or 
surprise; all tests p>0.05. Correlational analysis revealed that emotion recognition accuracy 
was negatively related to self-rated alexithymia; r(40)=-0.32, p<0.05. However, emotion 
recognition accuracy was not significantly related to self rated somatization; either SOMS 
score, r(20)=-0.3, p>0.05 or score on the somatization subscale of the SCL-90, r(20)=-0.2, 
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p>0.05. Importantly, emotion recognition accuracy was not significantly related to patients’ 
depression-scores (HAMD), SCL-90-R scores (GSI and depression scale); r(20)=-0.2, 
p>0.05; r(20)=-0.1, p>0.05 and r(20)=-0.2, p>0.05 respectively. Similarly, emotion recognition 
accuracy was not significantly related to the severity of the patients’ anxiety (indexed by 
SCL-90-R anxiety subscale); r(20)=-0.2, p>0.05. The re-analysis of the participants’ emotion 
recognition accuracy (FEEL scores) using an ANCOVA to control for the influence of 
alexithymia revealed that there was still a significant main effect of type of emotion; F(5, 
185)=2.5, p>0.05. However, the main effect of group was no longer significant; F(1, 38)=2.0, 
p>0.05. The ANCOVA also revealed no significant effect of alexithymia, no significant group 
x emotion interaction and no significant alexithymia x emotion interaction; F(1, 37)=2.6, 
p>0.05; F(5, 185)=0.7, p>0.05 and F(5, 185)=0.8, p>0.05 respectively. The adjusted mean 
FEEL scores on which these analyses were conducted are presented in table 3.   
 
DISCUSSION 
The primary aim of the present study was to examine if patients with SFD exhibited 
impaired facial emotion recognition. Also of interest was the extent to which the presence of 
concurrent alexithymia contributed to any observed changes in emotion recognition 
accuracy.  
In line with our predictions, patients with SFD correctly recognized fewer emotional 
expressions than did the healthy controls. This finding is consistent with the findings of 
Buhlmann et al. [2004; 2006], who reported that patients with body dysmorphic disorder (a 
subtype of SFD) exhibited a similar general deficit in the recognition of facial emotion. This 
suggests that impaired facial emotion recognition might be a general feature of SFD.  
As expected, patients with SFD rated themselves as significantly more alexithymic 
(on the TAS-26) than did the controls. This finding is consistent with previous studies that 
have reported elevated alexithymia scores in patients with SFD [Bach and Bach, 1995; 
Bankier et al., 2001]. However, it is important to note that, although the two groups of 
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participants differed in terms of their global TAS-26 scores, this finding is probably a 
consequence of the underlying deficit indexed by the factor 1 of TAS-26 (“Difficulty identifying 
feelings”); as, importantly, the two groups did not differ significantly on the other two factors 
of the TAS-26 (“Difficulty describing feelings” and “Externally oriented thinking”).  
The results of the ANCOVA revealed that once the influence of alexithymia was 
controlled for the observed difference between the two groups in terms of facial emotion 
recognition was no longer significant. This suggests that the observed impairment in emotion 
recognition exhibited by the patients with SFD was most likely a consequence of concurrent 
alexithymia. This finding is consistent with previous studies that have reported impaired 
emotion recognition in participants with elevated levels of alexithymia [e.g. Jessimer et al., 
1997; Lane et al., 2000; Parker et al., 1993]. Similarly, the observed negative correlation 
between participants alexithymia (TAS-26) scores and their performance on the FEEL task is 
also consistent with previous studies [Lane et al., 2000]. The present findings have 
implications for the ongoing study of alexithymia, as they support the notion that alexithymia 
might represent a general impairment in emotional processing. Furthermore, these results 
suggest that the presence of co-morbid alexithymia might contribute to emotion recognition 
deficits that have been reported in certain clinical disorders, most notably depression, eating 
disorders and obsessive-compulsive disorder [Aigner et al., 2006, Dannlowski et al., 2006, 
Gaebel et al., 1992; Gaebel et al., 2004; Leppänen et al., 2004; Weniger et al., 2004]. 
As previous studies [e.g. Amin et al., 2004; Mueser et al., 2004] have reported that, in 
certain psychiatric groups, impaired processing of emotional facial expressions is related to 
deficits in social functioning, it is plausible that the reported impairment of facial emotion 
recognition exhibited in the patients with SFD could also have implications for their social 
functioning. This is important as poor social support has been identified as a significant factor 
in the maintenance of ongoing psychological distress and in the development of mental 
illness [Hipkins et al., 2004; Klineberg et al., 2006]. This proposal could be examined in 
future research using recognized measures of social functioning, such as the social 
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functioning scale [Birchwood et al., 1999] or social problem solving task [Goddard et al., 
1996,1997]. 
Analysis of the participants’ FEEL scores revealed some general differences in the 
accuracy with which the participants could recognize the different emotional expressions. 
Notably, happiness and anger were recognized more accurately than all other emotional 
expressions (surprise, fear, disgust and sadness). An explanation for this recognition 
advantage for happy and angry expression may be found by referring to approach/withdrawal 
theories of emotion. For example, Davidson and Irwin [1999] postulated that there are 
basically two opposing systems relating to emotion: approach and withdrawal. It is generally 
suggested that happiness and anger are part of the approach system. It is therefore 
interesting that our participants exhibited enhanced recognition of the ‘approach’ emotions. In 
large samples of healthy subjects [N=400, Traue, Keller, Hoffmann, Kessler, in preparation], 
happiness and anger were consistently the two emotions that were recognized best. 
Moreover, the findings of the present study are consistent with evolutionary theories of 
emotion; as these theories would predict a recognition advantage for expressions that have 
the greatest fitness benefits for the individual. The smile is used by both sexes in social 
interactions to indicate approval and to signal potential interest in terms of mating, thus 
missing or misinterpreting this signal could have negative consequences for the individuals’ 
genetic fitness. Anger, on the other hand, is used to signal displeasure and to moderate the 
behaviour of others around us, thus insensitivity to this expression could result in physical 
danger for the individual, again negatively impacting upon genetic fitness [Davidson and 
Irwin, 1999]. However, it is also possible that happy and angry expressions involve more 
pronounced changes in facial muscle configurations that may have facilitated their 
recognition. Nevertheless, previous studies using other emotional stimuli [e.g. emotional tone 
of voice; Hornack et al., 2003] have also reported enhanced recognition of anger and 
happiness, suggesting that differences in facial configuration is not a complete explanation. 
There are a number of limitations to the present study that need to be considered. 
The first concerns the relatively low number of males in both participant samples (patients 
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and controls), which could have influenced the results of our study. For example, studies 
based on samples from the general population have tended to reported higher levels of 
alexithymia in males relative to females [Parker et al., 2003]. However, it should be noted 
that, other studies have reported no association between alexithymia and gender [Loas et al., 
2001]. Furthermore, in the present study, there was no significant difference between the two 
participant groups in terms of the ratio of males and females, thus the emotion recognition 
deficit observed in the patients with SFD is unlikely to be a consequence of gender 
differences. As the primary aim of the present study was to investigate facial emotion 
recognition in patients with SFD, it was not considered of primary importance to ensure that 
equal numbers of males and females were recruited, only that the balance of gender in the 
two groups was equivalent. However, given that previous studies [e.g. Thayer et al., 2000] 
have suggested that males and females process emotional stimuli differently (e.g. female 
participants report that they experience more intense emotional reactions than do males 
when making affective judgements of Ekman faces), future studies should also consider 
analysing gender differences.  
Another limitation of the present study concerns the high comorbidity between SFD 
and other psychiatric conditions; notably depressive disorders. This comorbidity has 
implications for the interpretation of the present findings in terms of the “pure” effects of 
somatization and alexithymia, as many studies have reported emotion recognition deficits in 
patients experiencing significant depression [e.g. Mikhailova, 1996; Weniger et al., 2004]. 
The high comorbidity between SFD and depressive symptoms has been well-reported in the 
literature [Rief et al., 1998; Maier and Falkai, 1999], thus it is plausible that the emotion 
recognition deficit observed in the patients with SFD could relate to comorbid depression. 
However, contrary to this notion, emotion recognition accuracy was not significantly 
correlated with clinician-rated depression severity or depression scales of the SCL-90. In 
order to delineate the effects of depression, alexithymia and somatoform symptoms on facial 
emotion recognition, future studies should compare alexithymic and non-alexithymic patients 
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with SFD, alexithymic and non-alexithymic patients with depression (but without symptoms of 
SFD) and healthy controls.    
Another limitation concerning the present sample is the fact that the participants in the 
control group were not assessed as thoroughly as the SFD patients with regards to the 
presence of medical and psychiatric conditions. However, the presence of undetected 
psychiatric conditions in the controls would have influenced the results in the opposite 
direction to our hypotheses (i.e. decreased the emotion recognition accuracy of the controls 
where we hypothesised that they would have a recognition advantage relative to the patients 
with SFD). A strength of the present study was that none of the patients or healthy controls 
were receiving medication at the time of testing, thus avoiding potential emotion recognition 
deficits due to pharmacological influences on the participants’ cognitive function. 
Another important point is the nosology of SFD. There are difficult conditions to 
conceptualize and classify the SFD [Sharpe and Carson, 2001]; in psychiatry, they are 
classified as somatoform disorders (DSM-IV/ICD-10) while in medicine as functional somatic 
syndromes. A common ground in these classifications appears to be the lack of a 
conventionally defined explanation for somatic presentations. A further problem is how to 
deal with the overlapping of psychosomatic issues with other psychiatric conditions, e.g. 
depressive disorders [Mayou et al., 2005]. The DSM-IV/ICD-10 Somatoform category is 
simply a grouping of favorites not a conceptual framework [Janca, 2005; Sykes, 2006]. A 
multi-factorial etiology with interacting psychological, social, and biological factors [Mayou et 
al., 1995] would be preferable. 
 
In summary, we reported that a selected sample of patients with SFD exhibited 
significantly impaired facial emotion recognition (indexed by scores on a reliable and valid 
measure of emotion recognition accuracy; the FEEL Test) relative to a group of healthy 
controls. To our knowledge this is the first study to report deficits in facial emotion recognition 
in patients with SFD (other than Body Dysmorphic Disorder). However, importantly, when 
concurrent alexithymia was controlled for this group difference became non-significant, which 
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suggests that the observed impairment of emotion recognition in the patients with SFD was a 
consequence of concurrent alexithymia. Finally, it is plausible that the deficit in the 
recognition of facially expressed emotion exhibited by the patients with SFD could lead to 
impaired social functioning in these patients. 
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Table 1: Mean alexithymia (TAS-26) scores for patients with SFD and healthy controls 
(Standard deviations are presented in parentheses)  
 
Scores on the TAS-26 Patients with SFD 
(N=20) 
Healthy Controls 
(N=20) p-value 
 Mean (SD) Mean (SD) 
 
Total Score 52.7 (9.9) 42.9 (10.5) p = 0.004* 
Factor 1 ”Difficulty 
identifying feelings“  56.0 (10.1) 44.6 (8.2) p < 0.001* 
Factor 2 “Difficulty 
describing feelings”  49.7 (13.4) 44.5 (11.5) p = 0.193 
Factor 3 “Externally 
orientated thinking”  48.6 (9.3) 45.6 (10.4) p = 0.334 
* Significant at the adjusted alpha level of 0.0125   
 
 
 23 
Table 2:    Mean emotion recognition (FEEL) scores for patients with SFD and healthy 
controls as a function of the type of emotional expression (Standard deviations are presented 
in parentheses)  
Type of Emotion Patients with SFD 
 (N = 20) 
Healthy Controls 
(N = 20) 
 Mean (SD) Mean (SD) 
Fear 4.6 (1.6) 4.5 (1.7) 
Sadness 3.9 (1.8) 5.1 (1.5) 
Anger 6.1 (0.9) 6.8 (0.4) 
Disgust 4.9 (2.1) 5.5 (1.3) 
Happiness 6.6 (0.7) 6.8 (0.6) 
Surprise 5.7 (1.4) 6.0 (1.2) 
Total FEEL score 31.7 (4.6)* 34.5 (3.0)* 
* Significantly different at 0.01 level 
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Table 3:    Adjusted Mean emotion recognition (FEEL) scores for patients with SFD and 
healthy controls as a function of the type of emotional expression (Standard deviations are 
presented in parentheses)  
Type of Emotion Patients with SFD 
 (N = 20) 
Healthy Controls 
(N = 20) 
 Mean (SD) Mean (SD) 
Fear 5.0 (1.6) 5.4 (1.7) 
Sadness 4.4 (1.8) 4.6 (1.5) 
Anger 6.2 (0.9) 6.7 (0.4) 
Disgust 6.7 (2.1) 6.7 (1.3) 
Happiness 4.0 (0.7) 4.0 (0.6) 
Surprise 5.8 (1.4) 5.8 (1.2) 
Total FEEL score 32.1 (4.6) 33.2 (3.0) 
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